RAC 0.55% $1.81 race oncology ltd

Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-17

  1. 1,510 Posts.
    lightbulb Created with Sketch. 378
    I’m particular encouraged by Peter’s comment.

    ”Executive Director, Dr Pete Smith commented: “These are highly positive outcomes in a heavily pre- treated patient population. We await with interest the release of the poster at ASH in December. To see such meaningful clinical responses in a group that would typically be receiving palliative care is striking. It is also encouraging that the safety profile was manageable, even for this advanced patient population.””

    No eagerly await the professional social media, interview appearances to get the word out.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.81
Change
-0.010(0.55%)
Mkt cap ! $307.3M
Open High Low Value Volume
$1.83 $1.84 $1.78 $271.2K 150.5K

Buyers (Bids)

No. Vol. Price($)
1 500 $1.80
 

Sellers (Offers)

Price($) Vol. No.
$1.81 349 1
View Market Depth
Last trade - 16.10pm 27/06/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.